NCT00047021View on ClinicalTrials.gov

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

August 31, 2005

Study Completion Date

September 30, 2005

Conditions
LeukemiaLymphoma
Interventions
BIOLOGICAL

sargramostim

Sargramostim (GM-CSF) subcutaneously beginning on day 14 and continuing until blood counts recover.

DRUG

cytarabine

high-dose cytarabine IV over 1 hour on days 1-5

DRUG

mitoxantrone hydrochloride

high-dose mitoxantrone IV over 15-30 minutes on day 5.

Trial Locations (1)

44106-7284

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT00047021 - Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma | Biotech Hunter | Biotech Hunter